Liver function and drug levels: a repotrectinib study
NCT ID NCT06352528
First seen Oct 31, 2025 · Last updated Jun 11, 2026 · Updated 37 times
Summary
This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for patients with liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
-
Panax Clinical Research
Miami Lakes, Florida, 33014-2811, United States
-
The Texas Liver Institute, Inc.
San Antonio, Texas, 78215, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.